The CONKO-001 trial established the benefit of which adjuvant treatment in resected pancreatic ductal adenocarcinoma?

• A Adjuvant gemcitabine chemotherapy ✓
• B Adjuvant chemoradiotherapy with 5-fluorouracil
• C Neoadjuvant FOLFIRINOX followed by surgery
• D Adjuvant erlotinib (EGFR inhibitor)

Explanation

The CONKO-001 (Charité Onkologie 001) trial randomized patients with resected pancreatic cancer to adjuvant gemcitabine versus observation. Gemcitabine significantly improved disease-free survival and overall survival compared to observation alone. This established gemcitabine as the standard of care for adjuvant treatment post-Whipple's pancreaticoduodenectomy. Subsequently, the ESPAC-4 trial showed that gemcitabine plus capecitabine was superior to gemcitabine alone.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.